Table 5 Appraisal of Guidelines for Research and Evaluation (AGREE) II reporting grid summary from four independent assessors
AGREE II Item | Reporting Location | Domain Score (%)b |
|---|---|---|
Domain 1. Scope and Purpose | 100 | |
1. The overall objective(s) of the guideline is (are) specifically described. | 鈥� Guideline Development Report 鈥� This manuscript | |
2. The health question(s) covered by the guideline is (are) specifically described. | 鈥� Guideline Development Report 鈥� This manuscript 鈥� Systematic reviews [18, 21,22,23] and PROSPERO Registrations | |
3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described. | 鈥� Guideline Development Report 鈥� This manuscript | |
Domain 2. Stakeholder Involvement | 99 | |
4. The guideline development group includes individuals from all the relevant professional groups. | 鈥� Guideline Development Report 鈥� This manuscript | |
5. The views and preferences of the target population (patients, public, etc.) have been sought. | 鈥� Guideline Development Report 鈥� This manuscript 鈥� Focus groups and key informant interviews [33] | |
6. The target users of the guideline are clearly defined. | 鈥� Guideline Development Report 鈥� This manuscript | |
Domain 3. Rigour of Development | 95 | |
7. Systematic methods were used to search for evidence. | 鈥� Guideline Development Report | |
8. The criteria for selecting the evidence are clearly described. | 鈥� Guideline Development Report | |
9. The strengths and limitations of the body of evidence are clearly described. | 鈥� Guideline Development Report 鈥� This manuscript | |
10. The methods for formulating the recommendations are clearly described. | 鈥� Guideline Development Report 鈥� This manuscript | |
11. The health benefits, side effects, and risks have been considered in formulating the recommendations. | 鈥� Guideline Development Report 鈥� This manuscript | |
12. There is an explicit link between the recommendations and the supporting evidence. | 鈥� Guideline Development Report | |
13. The guideline has been externally reviewed by experts prior to its publication. | 鈥� Guideline Development Report 鈥� This manuscript 鈥� Focus groups and key informant interviews [33] | |
14. A procedure for updating the guideline is provided. | 鈥� Guideline Development Report 鈥� This manuscript | |
Domain 4. Clarity of Presentation | 99 | |
15. The recommendations are specific and unambiguous. | 鈥� Guideline Development Report 鈥� This manuscript | |
16. The different options for management of the condition or health issue are clearly presented.a | 鈥� Not applicable | |
17. Key recommendations are easily identifiable. | 鈥� Guideline Development Report 鈥� This manuscript | |
Domain 5. Applicability | 89 | |
18. The guideline describes facilitators and barriers to its application. | 鈥� Guideline Development Report 鈥� This manuscript 鈥� Focus groups and key informant interviews [33] | |
19. The guideline provides advice and/or tools on how the recommendations can be put into practice. | 鈥� Guideline Development Report 鈥� This manuscript 鈥� CSEP website () | |
20. The potential resource implications of applying the recommendations have been considered. | 鈥� Guideline Development Report 鈥� This manuscript | |
21. The guideline presents monitoring and/or auditing criteria. | 鈥� Guideline Development Report 鈥� This manuscript | |
Domain 6. Editorial Independence | 89 | |
22. The views of the funding body have not influenced the content of the guideline. | 鈥� Guideline Development Report 鈥� This manuscript | |
23. Competing interests of guideline development group members have been recorded and addressed. | 鈥� This manuscript | |